Search - tctmd.com

Displaying 321 - 340 of 558

Sort: Relevancy | Date

News Daily News

Test de troponina I de alta sensibilidad podría eliminar el IM en gran número de pacientes

Todd Neale

October 13, 2015

News Daily News

High-Sensitivity Troponin I Assay May Rule Out MI in Large Number of Patients

Todd Neale

October 13, 2015

News Industry News

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

September 29, 2015

News Daily News

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

L.A. McKeown

September 21, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

L.A. McKeown

September 21, 2015

News Industry News

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

September 10, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Daily News

RITA 3的结果发布：对NSTE-ACS采取的常规侵入性策略在10年时失去优势

July 30, 2015

News Daily News

RITA 3 Published: Routine Invasive Strategy in NSTE-ACS Loses Advantage at 10 Years

July 30, 2015

News Daily News

RITA 3 Publicado: La Estrategia Invasiva Rutinaria en SCASEST Pierde su Ventaja a los 10 Años

July 30, 2015

News Features

Opportunities Exist for Hospitals, Interventionalists to Stave Off Unnecessary Readmissions

July 28, 2015

News Industry News

Micell Technologies Announces First Patient Enrolled in Registration Trial of MiStent SES in China

July 22, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Daily News

在较年轻的患者中，女性比男性更可能在发生急性心梗后再次入院

June 26, 2015

Advertisement

Test de troponina I de alta sensibilidad podría eliminar el IM en gran número de pacientes

High-Sensitivity Troponin I Assay May Rule Out MI in Large Number of Patients

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

RITA 3的结果发布：对NSTE-ACS采取的常规侵入性策略在10年时失去优势

RITA 3 Published: Routine Invasive Strategy in NSTE-ACS Loses Advantage at 10 Years

RITA 3 Publicado: La Estrategia Invasiva Rutinaria en SCASEST Pierde su Ventaja a los 10 Años

Opportunities Exist for Hospitals, Interventionalists to Stave Off Unnecessary Readmissions

Micell Technologies Announces First Patient Enrolled in Registration Trial of MiStent SES in China

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

在较年轻的患者中，女性比男性更可能在发生急性心梗后再次入院

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content